Advanced

Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry

Johnson, B A; Mann, K; Willenbring, M L; Litten, R Z; Swift, R M; Lesch, O M and Berglund, Mats LU (2005) In Alcoholism: Clinical and Experimental Research 29(8). p.1528-1540
Abstract
This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antagonist, cannabinoid, acamprosate, naltrexone, ondansetron, alcohol, topiramate
in
Alcoholism: Clinical and Experimental Research
volume
29
issue
8
pages
1528 - 1540
publisher
Wiley-Blackwell
external identifiers
  • wos:000231767900021
  • pmid:16156050
  • scopus:24144470778
ISSN
0145-6008
DOI
10.1097/01.alc.0000174690.63787.fc
language
English
LU publication?
yes
id
317c4acc-e7cc-4d26-9848-bd0f103d83e1 (old id 225115)
date added to LUP
2007-08-07 14:41:33
date last changed
2017-01-01 05:00:32
@article{317c4acc-e7cc-4d26-9848-bd0f103d83e1,
  abstract     = {This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.},
  author       = {Johnson, B A and Mann, K and Willenbring, M L and Litten, R Z and Swift, R M and Lesch, O M and Berglund, Mats},
  issn         = {0145-6008},
  keyword      = {antagonist,cannabinoid,acamprosate,naltrexone,ondansetron,alcohol,topiramate},
  language     = {eng},
  number       = {8},
  pages        = {1528--1540},
  publisher    = {Wiley-Blackwell},
  series       = {Alcoholism: Clinical and Experimental Research},
  title        = {Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry},
  url          = {http://dx.doi.org/10.1097/01.alc.0000174690.63787.fc},
  volume       = {29},
  year         = {2005},
}